These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 31983653)

  • 21. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
    Carey KM; Comee MR; Donovan JL; Kanaan AO
    Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polypill Strategy in Secondary Cardiovascular Prevention.
    Castellano JM; Pocock SJ; Bhatt DL; Quesada AJ; Owen R; Fernandez-Ortiz A; Sanchez PL; Marin Ortuño F; Vazquez Rodriguez JM; Domingo-Fernández A; Lozano I; Roncaglioni MC; Baviera M; Foresta A; Ojeda-Fernandez L; Colivicchi F; Di Fusco SA; Doehner W; Meyer A; Schiele F; Ecarnot F; Linhart A; Lubanda JC; Barczi G; Merkely B; Ponikowski P; Kasprzak M; Fernandez Alvira JM; Andres V; Bueno H; Collier T; Van de Werf F; Perel P; Rodriguez-Manero M; Alonso Garcia A; Proietti M; Schoos MM; Simon T; Fernandez Ferro J; Lopez N; Beghi E; Bejot Y; Vivas D; Cordero A; Ibañez B; Fuster V;
    N Engl J Med; 2022 Sep; 387(11):967-977. PubMed ID: 36018037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reaching blood pressure guideline targets with the CNIC polypill in patients with a previous cardiovascular event in Mexico: a
    Gómez-Álvarez E; Verdejo J; Ocampo S; Ruiz E; Martinez-Rios MA
    Future Cardiol; 2020 Jan; 16(1):53-60. PubMed ID: 31850802
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study.
    Castellano JM; Verdejo J; Ocampo S; Rios MM; Gómez-Álvarez E; Borrayo G; Ruiz E; Ibáñez B; Fuster V;
    Arch Med Res; 2019 Jan; 50(1):31-40. PubMed ID: 31101241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial.
    Lafeber M; Grobbee DE; Schrover IM; Thom S; Webster R; Rodgers A; Visseren FL; Bots ML; Spiering W
    Int J Cardiol; 2015 Feb; 181():193-9. PubMed ID: 25528311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe.
    Grigorian-Shamagian L; Edel K; Esteve-Pastor MA; Aceña Á; Silva C; Delgado-Silva J; Ntaios G; Demerouti E; Brotons C
    Front Cardiovasc Med; 2021; 8():663361. PubMed ID: 34504874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial.
    Bosch JJ; O'Donnell MJ; Gao P; Joseph P; Pais P; Xavier D; Dans A; Lopez Jaramillo P; Yusuf S
    JAMA Neurol; 2023 Mar; 80(3):251-259. PubMed ID: 36716007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries.
    Webster R; Patel A; Selak V; Billot L; Bots ML; Brown A; Bullen C; Cass A; Crengle S; Raina Elley C; Grobbee DE; Neal B; Peiris D; Poulter N; Prabhakaran D; Rafter N; Stanton A; Stepien S; Thom S; Usherwood T; Wadham A; Rodgers A;
    Int J Cardiol; 2016 Feb; 205():147-156. PubMed ID: 26736090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
    Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM.
    Oigman W; Gomes MA; Pereira-Barretto AC; Póvoa R; Kohlmann O; Rocha JC; Nobre F
    Clin Ther; 2013 May; 35(5):702-10. PubMed ID: 23623755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill.
    González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):547-50. PubMed ID: 27062678
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update to the Consensus Document on Clinical Use of the Polypill: New Dose Containing Atorvastatin 40 mg.
    González-Juanatey JR
    Rev Esp Cardiol (Engl Ed); 2018 Jul; 71(7):595-596. PubMed ID: 29752030
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study.
    Aguiar C; Araujo F; Rubio-Mercade G; Carcedo D; Paz S; Castellano JM; Fuster V
    J Health Econ Outcomes Res; 2022; 9(2):134-146. PubMed ID: 36475278
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The polypill as cardiovascular prophylactic: clinical trials].
    Sandli OK; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2014 Mar; 134(6):620-3. PubMed ID: 24670510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.